StressMarq biosciences - alpha synuclein oligomer antibody validation

StressMarq biosciences - α 突触核蛋白寡聚体抗体验证

• 批准号: 509804-2017
• 负责人: Christie, Brian
• 金额: $ 1.82万
• 依托单位: University of Victoria
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=640494
• 关键词: StressMarq; biosciences; alpha; synuclein; oligomer

This project will allow StressMarq, a company that specializes in making antibodies, and Dr. Christie'slaboratory at the University of Victoria to investigate a novel alpha synuclein aggregate. This aggregate hasprion-like properties, and is able - when active - to catalyze the formation of Lewy Bodies in vivo fromendogenous alpha synuclein monomers found in the host environment. Lewy Bodies are a hallmark of LewyBody dementia, often described as being a subset of Parkinson's disease (approximately 25% of Parkinson'spatients have this pathology). The project will involve "mapping" the expression of the pathology and activityof the antibody using immunohistochemistry on rat or mouse brain slices harvested from animals with varyingcontrolled neurological backgrounds, something routinely done in the Christie laboratory. The ability to workwith cell culture would show if the antibody can neutralize the Lewy Body pathology when induced in thesecells, and if successful, the same could be carried out in rats.

该项目将使专门制造抗体的StressMarq公司和维多利亚大学的克里斯蒂博士的实验室能够研究一种新的阿尔法突触核蛋白聚合体。这种聚集体具有蛋白样属性，当被激活时，能够催化在宿主环境中发现的内源性α突触核蛋白单体在体内形成路易小体。路易小体是路易体痴呆的一个特征，通常被描述为帕金森氏病的一个子集(大约25%的帕金森氏症患者有这种病理)。该项目将包括使用免疫组织化学技术在大鼠或小鼠脑片上绘制出抗体的病理和活性表达图，这些切片来自具有不同受控神经背景的动物，这是克里斯蒂实验室的常规工作。利用细胞培养的能力将表明，当在这些细胞中诱导时，抗体是否能够中和路易体的病理，如果成功，也可以在大鼠身上进行同样的实验。